Targeting the Hippo-YAP 
signaling pathway to
enhance treatment
for patients with
resistant cancer.
 
 

ABOUT

At Nivien, we are driven to help people with cancer and other diseases live longer, healthier lives. 

 

We are a startup from the IndieBio Accelerator and Harvard Innovation Labs with a therapeutic strategy based on novel biology from Harvard Medical School.

 

Our molecules harness the potential of the Hippo-YAP signaling pathway to treat cancer and other indications where Hippo plays an important role. We have patented the first inhibitors of the LATS1/2 kinases and are currently in preclinical testing for several cancers.

 

 

Cancer Resistance 

Defeating mechanisms that resistant, difficult-to-treat cancers use to evade drug-induced cell death

Tissue Repair 

Overcoming irreversible tissue damage such as fibrosis to promote healthier, better-functioning organs

Cardiac Regeneration

Increasing cell proliferation to improve cardiac function after myocardial infarction

NIVIEN

 

FOUNDERS

NATHANIEL BROOKS HORWITZ
CEO
DHARMENDRA SINGH, PH.D.
Scientist, Cancer Biology
NIKITA SHAH
President & CFO
W. KEN FANG, PH.D.
SVP, Medicinal Chemistry
 

ADVISORS

MARC KIRSCHNER, PH.D.
Harvard Medical School
 
MOTAZ QADAN, M.D., PH.D.
Massachusetts General Hospital
DERRICK ROSSI, PH.D.
Boston Children's Hospital
 

INVESTORS

 
 
Contact Us
Email
nathaniel@generalbiotechnologies.com
nikita@generalbiotechnologies.com
Nivien at the IndieBio Accelerator
479 Jessie Street, San Francisco
California, 94103
Nivien at the Harvard Innovation Labs
125 Western Avenue, Boston
Massachusetts, 02163

© 2017 — Nivien Therapeutics Company